Format
Sort by

Send to

Choose Destination

Search results

Items: 13

1.

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.

Pialoux G, Marcelin AG, Despiégel N, Espinas C, Cawston H, Finkielsztejn L, Laurisse A, Aubin C.

PLoS One. 2015 Dec 29;10(12):e0145885. doi: 10.1371/journal.pone.0145885. eCollection 2015.

2.

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada.

Despiégel N, Anger D, Martin M, Monga N, Cui Q, Rocchi A, Pulgar S, Gilchrist K, Refoios Camejo R.

Infect Dis Ther. 2015 Sep;4(3):337-53. doi: 10.1007/s40121-015-0071-0. Epub 2015 Jun 23.

3.

Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.

Bayoumi AM, Barnett PG, Joyce VR, Griffin SC, Sun H, Bansback NJ, Holodniy M, Sanders G, Brown ST, Kyriakides TC, Angus B, Cameron DW, Anis AH, Sculpher M, Owens DK.

J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):382-91. doi: 10.1097/QAI.0000000000000002.

4.

Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

Simpson KN, Pei PP, Möller J, Baran RW, Dietz B, Woodward W, Migliaccio-Walle K, Caro JJ.

Pharmacoeconomics. 2013 May;31(5):427-44. doi: 10.1007/s40273-013-0048-3.

PMID:
23620210
5.

Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study.

Nichols BE, Boucher CA, van Dijk JH, Thuma PE, Nouwen JL, Baltussen R, van de Wijgert J, Sloot PM, van de Vijver DA.

PLoS One. 2013;8(3):e59549. doi: 10.1371/journal.pone.0059549. Epub 2013 Mar 18.

6.

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.

von Wyl V, Cambiano V, Jordan MR, Bertagnolio S, Miners A, Pillay D, Lundgren J, Phillips AN.

PLoS One. 2012;7(8):e42834. doi: 10.1371/journal.pone.0042834. Epub 2012 Aug 8.

7.

Cost-effectiveness of raltegravir in HIV/AIDS.

Chaudhary MA, Elbasha EH, Kumar RN, Nathanson EC.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):627-39. doi: 10.1586/erp.11.79. Review.

PMID:
22098278
8.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:147-67. doi: 10.2165/11587500-000000000-00000.

PMID:
21182349
9.

A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals.

Kühne FC, Chancellor J, Mollon P, Myers DE, Louie M, Powderly WG.

HIV Clin Trials. 2010 Mar-Apr;11(2):80-99. doi: 10.1310/hct1102-80.

PMID:
20542845
10.

The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach.

Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA.

HIV Med. 2007 Oct;8(7):439-50.

11.
12.

HIV resistance testing in clinical practice: a Qaly-fied success.

Saag MS.

Ann Intern Med. 2001 Mar 20;134(6):475-7. No abstract available.

PMID:
11255523
13.

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.

Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, Kimmel AD, Freedberg KA.

Ann Intern Med. 2001 Mar 20;134(6):440-50.

PMID:
11255519
Items per page

Supplemental Content

Loading ...
Write to the Help Desk